201 related articles for article (PubMed ID: 36455411)
21. Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement.
Valvi S; Manoharan N; Mateos MK; Hassall TE; Ziegler DS; McCowage GB; Dun MD; Eisenstat DD; Gottardo NG; Hansford JR
Med J Aust; 2024 Jun; 220(10):533-538. PubMed ID: 38699949
[TBL] [Abstract][Full Text] [Related]
22. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
[TBL] [Abstract][Full Text] [Related]
23. Biopsy of paediatric brainstem intrinsic tumours: Experience from a Singapore Children's Hospital.
Lim YG; Tan EE; Looi WS; Wong RX; Chang KT; Low DC; Seow WT; Low SY
J Clin Neurosci; 2022 Dec; 106():8-13. PubMed ID: 36228504
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
25. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
26. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
27. Diffuse midline glioma: review of epigenetics.
Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
[TBL] [Abstract][Full Text] [Related]
28. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
30. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
31. Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
Pfaff E; El Damaty A; Balasubramanian GP; Blattner-Johnson M; Worst BC; Stark S; Witt H; Pajtler KW; van Tilburg CM; Witt R; Milde T; Jakobs M; Fiesel P; Frühwald MC; Hernáiz Driever P; Thomale UW; Schuhmann MU; Metzler M; Bochennek K; Simon T; Dürken M; Karremann M; Knirsch S; Ebinger M; von Bueren AO; Pietsch T; Herold-Mende C; Reuss DE; Kiening K; Lichter P; Eggert A; Kramm CM; Pfister SM; Jones DTW; Bächli H; Witt O
Eur J Cancer; 2019 Jun; 114():27-35. PubMed ID: 31022591
[TBL] [Abstract][Full Text] [Related]
32. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
33. Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma.
Barua NU; Lowis SP; Woolley M; O'Sullivan S; Harrison R; Gill SS
Acta Neurochir (Wien); 2013 Aug; 155(8):1459-65. PubMed ID: 23595829
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
35. The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation.
Roig-Carles D; Jackson H; Loveson KF; Mackay A; Mather RL; Waters E; Manzo M; Alborelli I; Golding J; Jones C; Fillmore HL; Crea F
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502082
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
Erker C; Lane A; Chaney B; Leary S; Minturn JE; Bartels U; Packer RJ; Dorris K; Gottardo NG; Warren KE; Broniscer A; Kieran MW; Zhu X; White P; Dexheimer PJ; Black K; Asher A; DeWire M; Hansford JR; Gururangan S; Nazarian J; Ziegler DS; Sandler E; Bartlett A; Goldman S; Shih CS; Hassall T; Dholaria H; Bandopadhayay P; Samson Y; Monje M; Fisher PG; Dodgshun A; Parkin S; Chintagumpala M; Tsui K; Gass D; Larouche V; Broxson E; Garcia Lombardi M; Wang SS; Ma J; Hawkins C; Hamideh D; Wagner L; Koschmann C; Fuller C; Drissi R; Jones BV; Leach J; Fouladi M
Neuro Oncol; 2022 Jan; 24(1):141-152. PubMed ID: 34114629
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
38. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
39. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
40. A homogeneous treatment for non-DIPG diffuse midline glioma.
Schiavello E; Biassoni V; Gattuso G; Podda M; Chiaravalli S; Barretta F; Antonelli M; De Cecco L; Pecori E; Gandola L; Massimino M
Tumori; 2023 Jun; 109(3):269-275. PubMed ID: 35708347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
